BACKGROUND: The revised 2017 European LeukemiaNet (ELN) classification (ELN-2017) of acute myeloid leukemia (AML) divides patients into 3 prognostic risk categories, with additional factors such as the fms-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) allele ratio (AR) considered for risk stratification. To the best of the authors' knowledge, the prognostic usefulness of ELN-2017 in comparison with ELN-2010 in younger patients with AML has not been validated to date. METHODS: The authors performed a retrospective study on patients aged <60 years who received idarubicin plus cytarabine (IA)-based induction chemotherapy for newly diagnosed AML. RESULTS: According to ELN-2017 criteria, the number of patients in the favorable (Fav), intermediate (Int), and adverse (Adv) risk categories was 192 patients (27%), 331 patients (46%), and 192 patients (27%), respectively. Overall survival probabilities at 5 years in the Fav, Int, and Adv groups were 57%, 37%, and 18%, respectively. In comparison, the 5-year overall survival probabilities in the Fav (169 patients), intermediate (IR)-1 (80 patients), IR-2 (306 patients), and Adv (160 patients) ELN-2010 categories were 59%, 32%, 40%, and 14%, respectively. Although ELN-2010 historically distinguishes prognosis into IR-1 and IR-2 categories in younger patients, this difference was nullified in the current study cohort. When comparing patients with a low FLT3-ITD AR with those with a high FLT3-ITD AR, no significant differences in survival were noted among patients with nucleophosmin 1 (NPM1)-mutated AML (P = .28) or wild-type NPM1 (P = .35), and in those treated with IA alone (P = .79) or those treated with IA and a FLT3 inhibitor (P = .10). CONCLUSIONS: The ELN-2017 more accurately distinguishes prognosis in patients with newly diagnosed AML. The lack of prognostic significance for the FLT3-ITD AR needs further evaluation in different treatment settings.
BACKGROUND: The revised 2017 European LeukemiaNet (ELN) classification (ELN-2017) of acute myeloid leukemia (AML) divides patients into 3 prognostic risk categories, with additional factors such as the fms-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) allele ratio (AR) considered for risk stratification. To the best of the authors' knowledge, the prognostic usefulness of ELN-2017 in comparison with ELN-2010 in younger patients with AML has not been validated to date. METHODS: The authors performed a retrospective study on patients aged <60 years who received idarubicin plus cytarabine (IA)-based induction chemotherapy for newly diagnosed AML. RESULTS: According to ELN-2017 criteria, the number of patients in the favorable (Fav), intermediate (Int), and adverse (Adv) risk categories was 192 patients (27%), 331 patients (46%), and 192 patients (27%), respectively. Overall survival probabilities at 5 years in the Fav, Int, and Adv groups were 57%, 37%, and 18%, respectively. In comparison, the 5-year overall survival probabilities in the Fav (169 patients), intermediate (IR)-1 (80 patients), IR-2 (306 patients), and Adv (160 patients) ELN-2010 categories were 59%, 32%, 40%, and 14%, respectively. Although ELN-2010 historically distinguishes prognosis into IR-1 and IR-2 categories in younger patients, this difference was nullified in the current study cohort. When comparing patients with a low FLT3-ITD AR with those with a high FLT3-ITD AR, no significant differences in survival were noted among patients with nucleophosmin 1 (NPM1)-mutated AML (P = .28) or wild-type NPM1 (P = .35), and in those treated with IA alone (P = .79) or those treated with IA and a FLT3 inhibitor (P = .10). CONCLUSIONS: The ELN-2017 more accurately distinguishes prognosis in patients with newly diagnosed AML. The lack of prognostic significance for the FLT3-ITD AR needs further evaluation in different treatment settings.
Authors: Christoph Röllig; Martin Bornhäuser; Christian Thiede; Franziska Taube; Michael Kramer; Brigitte Mohr; Walter Aulitzky; Heinrich Bodenstein; Hans-Joachim Tischler; Reingard Stuhlmann; Ulrich Schuler; Friedrich Stölzel; Malte von Bonin; Hannes Wandt; Kerstin Schäfer-Eckart; Markus Schaich; Gerhard Ehninger Journal: J Clin Oncol Date: 2011-05-31 Impact factor: 44.544
Authors: David Grimwade; Robert K Hills; Anthony V Moorman; Helen Walker; Stephen Chatters; Anthony H Goldstone; Keith Wheatley; Christine J Harrison; Alan K Burnett Journal: Blood Date: 2010-04-12 Impact factor: 22.113
Authors: Hartmut Döhner; Elihu Estey; David Grimwade; Sergio Amadori; Frederick R Appelbaum; Thomas Büchner; Hervé Dombret; Benjamin L Ebert; Pierre Fenaux; Richard A Larson; Ross L Levine; Francesco Lo-Coco; Tomoki Naoe; Dietger Niederwieser; Gert J Ossenkoppele; Miguel Sanz; Jorge Sierra; Martin S Tallman; Hwei-Fang Tien; Andrew H Wei; Bob Löwenberg; Clara D Bloomfield Journal: Blood Date: 2016-11-28 Impact factor: 22.113
Authors: Jay P Patel; Mithat Gönen; Maria E Figueroa; Hugo Fernandez; Zhuoxin Sun; Janis Racevskis; Pieter Van Vlierberghe; Igor Dolgalev; Sabrena Thomas; Olga Aminova; Kety Huberman; Janice Cheng; Agnes Viale; Nicholas D Socci; Adriana Heguy; Athena Cherry; Gail Vance; Rodney R Higgins; Rhett P Ketterling; Robert E Gallagher; Mark Litzow; Marcel R M van den Brink; Hillard M Lazarus; Jacob M Rowe; Selina Luger; Adolfo Ferrando; Elisabeth Paietta; Martin S Tallman; Ari Melnick; Omar Abdel-Wahab; Ross L Levine Journal: N Engl J Med Date: 2012-03-14 Impact factor: 91.245
Authors: Hartmut Döhner; Elihu H Estey; Sergio Amadori; Frederick R Appelbaum; Thomas Büchner; Alan K Burnett; Hervé Dombret; Pierre Fenaux; David Grimwade; Richard A Larson; Francesco Lo-Coco; Tomoki Naoe; Dietger Niederwieser; Gert J Ossenkoppele; Miguel A Sanz; Jorge Sierra; Martin S Tallman; Bob Löwenberg; Clara D Bloomfield Journal: Blood Date: 2009-10-30 Impact factor: 22.113
Authors: Krzysztof Mrózek; Guido Marcucci; Deedra Nicolet; Kati S Maharry; Heiko Becker; Susan P Whitman; Klaus H Metzeler; Sebastian Schwind; Yue-Zhong Wu; Jessica Kohlschmidt; Mark J Pettenati; Nyla A Heerema; AnneMarie W Block; Shivanand R Patil; Maria R Baer; Jonathan E Kolitz; Joseph O Moore; Andrew J Carroll; Richard M Stone; Richard A Larson; Clara D Bloomfield Journal: J Clin Oncol Date: 2012-09-17 Impact factor: 44.544
Authors: Jan J Cornelissen; Alois Gratwohl; Richard F Schlenk; Jorge Sierra; Martin Bornhäuser; Gunnar Juliusson; Zdenek Råcil; Jacob M Rowe; Nigel Russell; Mohamad Mohty; Bob Löwenberg; Gerard Socié; Dietger Niederwieser; Gert J Ossenkoppele Journal: Nat Rev Clin Oncol Date: 2012-09-04 Impact factor: 66.675
Authors: Douglas R A Silveira; Lynn Quek; Itamar S Santos; Anna Corby; Juan L Coelho-Silva; Diego A Pereira-Martins; Grant Vallance; Benjamin Brown; Luciana Nardinelli; Wellington F Silva; Elvira D R P Velloso; Antonio R Lucena-Araujo; Fabiola Traina; Andy Peniket; Paresh Vyas; Eduardo M Rego; Israel Bendit; Vanderson Rocha Journal: Blood Adv Date: 2020-05-26
Authors: Era L Pogosova-Agadjanyan; Anna Moseley; Megan Othus; Frederick R Appelbaum; Thomas R Chauncey; I-Ming L Chen; Harry P Erba; John E Godwin; Isaac C Jenkins; Min Fang; Mike Huynh; Kenneth J Kopecky; Alan F List; Jasmine Naru; Jerald P Radich; Emily Stevens; Brooke E Willborg; Cheryl L Willman; Brent L Wood; Qing Zhang; Soheil Meshinchi; Derek L Stirewalt Journal: Biomark Res Date: 2020-08-12
Authors: Yan Huang; Juan Hu; Ting Lu; Yi Luo; Jimin Shi; Wenjun Wu; Xiaoyan Han; Weiyan Zheng; Jingsong He; Zhen Cai; Guoqing Wei; He Huang; Jie Sun Journal: Cancer Manag Res Date: 2019-05-08 Impact factor: 3.989
Authors: Sanam Loghavi; Courtney D DiNardo; Ken Furudate; Koichi Takahashi; Tomoyuki Tanaka; Nicholas J Short; Tapan Kadia; Marina Konopleva; Rashmi Kanagal-Shamanna; Noushin R Farnoud; Sherry Pierce; Joseph D Khoury; Jeffrey L Jorgensen; Keyur P Patel; Naval Daver; Musa Yilmaz; L Jeffrey Medeiros; Hagop Kantarjian; Farhad Ravandi; Sa A Wang Journal: Br J Haematol Date: 2021-02-22 Impact factor: 6.998
Authors: Ann-Kathrin Eisfeld; Jessica Kohlschmidt; Alice Mims; Deedra Nicolet; Christopher J Walker; James S Blachly; Andrew J Carroll; Dimitrios Papaioannou; Jonathan E Kolitz; Bayard E Powell; Richard M Stone; Albert de la Chapelle; John C Byrd; Krzysztof Mrózek; Clara D Bloomfield Journal: Leukemia Date: 2020-05-27 Impact factor: 11.528
Authors: Tobias Herold; Maja Rothenberg-Thurley; Victoria V Grunwald; Hanna Janke; Dennis Goerlich; Maria C Sauerland; Nikola P Konstandin; Annika Dufour; Stephanie Schneider; Michaela Neusser; Bianka Ksienzyk; Philipp A Greif; Marion Subklewe; Andreas Faldum; Stefan K Bohlander; Jan Braess; Bernhard Wörmann; Utz Krug; Wolfgang E Berdel; Wolfgang Hiddemann; Karsten Spiekermann; Klaus H Metzeler Journal: Leukemia Date: 2020-03-30 Impact factor: 11.528